Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

A study reveals SGLT-2 inhibitors significantly reduce dementia risk in type 2 diabetes patients, with effects strengthening ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study.

Their new study, published in The BMJ, reports on the benefits of using sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as they were associated with fewer dementia cases than people taking ...

Analysis of a large database of people aged 40-69 with type 2 diabetes found a 35% reduced risk of dementia associated with use of sodium-glucose cotransporter-2 (SGLT2) compared with dipeptidyl ...

They were compared with so-called dipeptidyl peptidase-4 inhibitors, a category that includes Novartis’s Galvus and Johnson & Johnson’s Invokana. The study, using data from South Korea’s ...

The Prolyl Endopeptidase FAP pipeline drugs market research report outlays comprehensive information on the Prolyl Endopeptidase FAP targeted therapeutics, complete with analysis by indications, stage ...

compared to those taking dipeptidyl peptidase-4 inhibitors or DPP-4 inhibitors, also known as gliptins. Further, treatment with SGLT-2 drugs over a long duration was found to have more pronounced ...

Diabetes drugs that cost £1 a day and are already available on the NHS could prevent the onset of dementia, a BMJ study has ...